Gerald E. Quirk - Mar 27, 2024 Form 4 Insider Report for Syros Pharmaceuticals, Inc. (SYRS)

Role
Chief Legal & Compliance Offic
Signature
/s/ Todd Rosenthal, as attorney-in-fact
Stock symbol
SYRS
Transactions as of
Mar 27, 2024
Transactions value $
-$39,387
Form type
4
Date filed
4/2/2024, 04:57 PM
Previous filing
Oct 20, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SYRS Common Stock Options Exercise +22.5K +92.58% 46.8K Mar 27, 2024 Direct F1
transaction SYRS Common Stock Tax liability -$39.4K -7.05K -15.05% $5.59 39.8K Mar 28, 2024 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SYRS Restricted Stock Units Options Exercise $0 -22.5K -100% $0.00* 0 Mar 27, 2024 Common Stock 22.5K Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock received upon vesting of a restricted stock unit award.
F2 Represents shares used to cover tax withholding on a restricted stock unit release.
F3 Each restricted stock unit represents the contingent right to receive one share of the issuer's common stock.
F4 Represents a restricted stock unit award granted on October 11, 2022. These restricted stock units vested as to one half (50%) of the shares on October 11, 2023, and vested as to one half (50%) of the shares on March 27, 2024.